Rakovina Therapeutics Announces Strategic Pivot to AI - Seite 2

Rakovina Strategic Information Conference Call

The Rakovina leadership team and members of the scientific team will be hosting a conference call to provide additional information about the company's new strategic direction and industry insights.

Conference Call Details:
Date:	April 3, 2024
Time:	10:00 a.m. Pacific Time (1:00 p.m. Eastern Time)
Link:	https://events.irlabs.ca/rkv_event

About Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration, and similar international regulatory agencies.

Led by a seasoned team of industry experts, Rakovina is well-positioned to drive innovation in the field of oncology. Bacha brings over 25 years of healthcare and life science experience, while Dr. Daugaard, brings decades of experience in DNA damage responses and translational cancer research.

Further information may be found at www.rakovinatherapeutics.com.

The Company's Scientific Advisory Board, chaired by Dr. Dennis Brown, is composed of esteemed scientists and researchers in the fields of science and cancer research. Members are Dr. Cherkasov, Dr. Petra Hamerlik, Dr. Leonard Post, and Dr. Wang Shen, who bring invaluable expertise to Rakovina Therapeutics' research and development efforts.

For Additional Information Contact:
Rakovina Therapeutics Inc.
David Hyman
Chief Financial Officer
Email: [e-mail]

Investor Relations Contact:
[e-mail]

Media Contact:
[e-mail]

The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice of Forward-Looking Statements

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”,“could”,“would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company.